Stocks
CymaBay Therapeutics, Inc.CBAY
NASDAQHealthcareBiotechnology$32.48+0.03%
A clinical-stage biopharmaceutical company focused on developing therapies for chronic liver and metabolic diseases. Its lead drug candidate, seladelpar, targets primary biliary cholangitis (PBC) and has been the central driver of investor attention due to late-stage clinical results and regulatory ...
Market Cap: $3.7B52W Range: $7.26 – $32.50
Congressional Interest in CymaBay Therapeutics, Inc. (CBAY)
1 member of Congress has disclosed 2 trades in CymaBay Therapeutics, Inc. (CBAY), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading CBAY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-07-19 | Roger W. Marshall | buy | $1K – $15K |
| 2017-07-19 | Roger W. Marshall | sell | $1K – $15K |